Procter & Gamble Health Ltd plans to discontinue production of injections at its manufacturing plant in Goa and source them from a contract manufacturer, with the change expected to achieve cost efficiency and supply optimization. The injections portfolio accounted for revenue of Rs. 102.92 crores in the financial year 2022-23, constituting 8.37% of the companys total revenue.